Cargando…
ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma
PAI-1 plays significant roles in cancer occurrence, relapse and multidrug resistance and is highly expressed in tumours. ACT001, which is currently in phase I clinical trials for the treatment of glioblastoma (GBM). However, the detailed molecular mechanism of ACT001 is still unclear. In this study,...
Autores principales: | Xi, Xiaonan, Liu, Ning, Wang, Qianqian, Chu, Yahui, Yin, Zheng, Ding, Yahui, Lu, Yaxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779874/ https://www.ncbi.nlm.nih.gov/pubmed/31591377 http://dx.doi.org/10.1038/s41419-019-1986-2 |
Ejemplares similares
-
Joint bioinformatics analysis of underlying potential functions of hsa-let-7b-5p and core genes in human glioma
por: Xi, Xiaonan, et al.
Publicado: (2019) -
Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling
por: Hou, Yanli, et al.
Publicado: (2021) -
Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin
por: Ni, Fan, et al.
Publicado: (2018) -
ACT001 inhibited CD133 transcription by targeting and inducing Olig2 ubiquitination degradation
por: Deng, Huiting, et al.
Publicado: (2023) -
Lupeol Alleviates Cerebral Ischemia–Reperfusion Injury in Correlation with Modulation of PI3K/Akt Pathway
por: Wang, Zhiwei, et al.
Publicado: (2020)